Bendamustine with total body irradiation conditioning yields tolerant T-cells while preserving T-cell-dependent graft-versus-leukemia

References

• van den Brink MRM, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, Bishop MR. Relapse after allogeneic hematopoietic cell therapy. Biol Blood Marrow Trans. 2010;16(1):S138–S145. doi:10.1016/j.bbmt.2009.10.023.
   PubMed Web of Science ®Google Scholar
• Stokes J, Hoffman EA, Zeng Y, Larmonier N, Katsanis E. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation. Br J Haematol. 2016;174:102–17. doi:10.1111/bjh.14034.
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010;47:65–77. doi:10.1007/s12026-009-8139-0.
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683–693. doi:10.1053/j.seminoncol.2012.09.005.
   PubMed Web of Science ®Google Scholar
• Katsanis E, Sapp LN, Varner N, Koza S, Stea B, Zeng Y. Haploidentical bone marrow transplantation with post-transplant cyclophosphamide/bendamustine in pediatric and young adult patients with hematologic malignancies. Biol Blood Marrow Transplant. 2018;24:2034–2039. doi:10.1016/j.bbmt.2018.06.007.
   PubMed Web of Science ®Google Scholar
• Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Zander T, Betticher D, Egger T, Rauch D, et al. BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol. 2017;96(3):421–429. doi:10.1007/s00277-016-2900-y.
   PubMed Web of Science ®Google Scholar
• Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG, Gentile M, Molica S, Morabito F. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Bone Marrow Transplant. 2016;51:1197–1203. doi:10.1038/bmt.2016.94.
   PubMed Web of Science ®Google Scholar
• Hueso T, Gastinne T, Garciaz S, Tchernonog E, Delette C, Casasnovas R-O, Durot E, Houot R, Tessoulin B, Tournilhac O, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplant. 2020. doi:10.1038/s41409-020-0783-y.
   PubMedGoogle Scholar
• Khouri IF, Wei W, Korbling M, Turturro F, Ahmed S, Alousi A, Anderlini P, Ciurea S, Jabbour E, Oran B, et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD. Blood. 2014;124(14):2306–2312. doi:10.1182/blood-2014-07-587519.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Sui D, Jabbour EJ, Samuels BI, Turturro F, Alatrash G, Anderlini P, Ahmed S, Oran B, Ciurea SO, et al. Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplant. 2017;52:28–33. doi:10.1038/bmt.2016.204.
   PubMed Web of Science ®Google Scholar
• Holter-Chakrabarty JL, Pierson N, Zhang M-J, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, et al. The sequence of cyclophosphamide and myeloablative total body irradiation in hematopoietic cell transplant for patients with acute leukemia. Biol Blood Marrow Transplant. 2015;21:1251–1257. doi:10.1016/j.bbmt.2015.03.017.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, O’Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA, Territo MC, Collins RH, McSweeney PA, Copelan EA, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108:1485–1491. doi:10.1182/blood-2006-03-005041.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Socie’ G, Lanino E, Prete A, Locatelli F, Locasciulli A, Cesaro S, Shimoni A, Marsh J, Brune M, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95(6):976–982. doi:10.3324/haematol.2009.018267.
   PubMed Web of Science ®Google Scholar
• Svenberg P, Remberger M, Svennilson J, Mattsson J, Leblanc K, Gustafsson B, Aschan J, Barkholt L, Winiarski J, Ljungman P, et al. Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors. Biol Blood Marrow Transplant. 2004;10(12):877–882. doi:10.1016/j.bbmt.2004.08.002.
   PubMed Web of Science ®Google Scholar
• Deeg HJ, Amylon MD, Harris RE, Collins R, Beatty PG, Feig S, Ramsay N, Territo M, Khan SP, Pamphilon D, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7(4):208–215. doi:10.1053/bbmt.2001.v7.pm11349807.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Luznik L, Bolaños-Meade J, Leffell MS, Jones RJ, Fuchs EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplantation. 2008;42(8):523–527. doi:10.1038/bmt.2008.203.
   PubMed Web of Science ®Google Scholar
• Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen–a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:3549–3556. doi:10.1200/JCO.2013.48.8114.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344–353. doi:10.1182/blood-2014-02-514778.
   PubMed Web of Science ®Google Scholar
• Stokes J, Hoffman EA, Molina MS, Eremija J, Larmonier N, Zeng Y, Katsanis E. Bendamustine with total body irradiation limits murine graft-versus-host disease in part through effects on myeloid-derived suppressor cells. Biol Blood Marrow Transplant. 2019;25:405–416. doi:10.1016/j.bbmt.2018.10.009.
   PubMed Web of Science ®Google Scholar
• Betts BC, Bastian D, Iamsawat S, Nguyen H, Heinrichs JL, Wu Y, Daenthanasanmak A, Veerapathran A, O’Mahony A, Walton K, et al. Targeting JAK2 reduces GVHD and xenograft rejection through regulation of T cell differentiation. Proc Natl Acad Sci U S A. 2018;115(7):1582–1587. doi:10.1073/pnas.1712452115.
   PubMed Web of Science ®Google Scholar
• Nikolic B, Lee S, Bronson RT, Grusby MJ, Sykes M. Th1 and Th2 mediate acute graft-versus-host disease, each with distinct end-organ targets. J Clin Invest. 2000;105:1289–1298. doi:10.1172/JCI7894.
   PubMed Web of Science ®Google Scholar
• Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, Luznik L. Donor CD4(+) Foxp3(+) regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014;124:2131–2141. doi:10.1182/blood-2013-10-525873.
   PubMed Web of Science ®Google Scholar
• Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+CD25+ regulatory T Cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196:389–399. doi:10.1084/jem.20020399.
   PubMed Web of Science ®Google Scholar
• Hotta M, Yoshimura H, Satake A, Tsubokura Y, Ito T, Nomura S. GM-CSF therapy inhibits chronic graft-versus-host disease via expansion of regulatory T cells. Eur J Immunol. 2019;49(1):179–191. doi:10.1002/eji.201847684.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sharpe AH, Vallera DA. Opposing roles of CD28: b7and CTLA-4: b7Pathways in Regulating In Vivo alloresponses in murine recipients of MHC disparate T cells. J Immunol. 1999;162:6368.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Carreno BM, Panoskaltsis-Mortari A, Carter L, Iwai Y, Yagita H, Nishimura H, Taylor PA. Blockade of programmed Death-1 engagement accelerates graft-versus-host disease lethality by an IFN-γ-dependent mechanism. J Immunol. 2003;171:1272. doi:10.4049/jimmunol.171.3.1272.
   PubMed Web of Science ®Google Scholar
• Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180–205. doi:10.1111/j.1600-065X.2011.01011.x.
   PubMed Web of Science ®Google Scholar
• Taylor PA, Panoskaltsis-Mortari A, Freeman GJ, Sharpe AH, Noelle RJ, Rudensky AY, Mak TW, Serody JS, Blazar BR. Targeting of inducible costimulator (ICOS) expressed on alloreactive T cells down-regulates graft-versus-host disease (GVHD) and facilitates engraftment of allogeneic bone marrow (BM). Blood. 2005;105:3372–3380. doi:10.1182/blood-2004-10-3869.
   PubMed Web of Science ®Google Scholar
• Chandrashekar DV, Suresh P, Kumar R, Bhamidipati R, Mullangi R, Richter W, Srinivas N. Sensitive LC-MS/MS method for the simultaneous determination of bendamustine and its active metabolite, gamma-hydroxybendamustine in small volume mice and dog plasma and its application to a pharmacokinetic study in mice and dogs. Drug Res. 2017;67:497–508. doi:10.1055/s-0043-108124.
   Web of Science ®Google Scholar
• Sadagopan N, Cohen L, Roberts B, Collard W, Omer C. Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution. J Chromatogr B Biomed Sci Appl. 2001;759:277–284. doi:10.1016/S0378-4347(01)00243-2.
   PubMedGoogle Scholar
• Srinivas NR, Richter W, Devaraj V, Suresh P, Bhamdipati R, Mullangi R. Infusion rate dependent pharmacokinetics of bendamustine with altered formation of gamma-hydroxybendamustine (M3) metabolite following 30- and 60-min infusion of bendamustine in rats. Drug Res. 2016;66:351–356. doi:10.1055/s-0042-105745.
   Web of Science ®Google Scholar
• Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte JJ, Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230–3239. doi:10.1182/blood.V88.8.3230.bloodjournal8883230.
   PubMed Web of Science ®Google Scholar
• Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, Yakoub-Agha I, Chevallier P, Ganser A, Blaise D, et al. Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study. Bone Marrow Transplant. 2020;55(1):224–232. doi:10.1038/s41409-019-0673-3.
   PubMed Web of Science ®Google Scholar
• Rubio MT, D’Aveni-Piney, M., Labopin, M., Hamladji, R.M., Sanz, M.A., Blaise, D., Ozdogu, H., Daguindeau, E., Richard, C., Santarone, S, et al. Impact of in vivo T cell depletion in HLA-identical allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission conditioned with a fludarabine iv-busulfan myeloablative regimen: a report from the EBMT Acute Leukemia Working Party. J Hematol Oncol. 2017;10:31.
   PubMed Web of Science ®Google Scholar
• Konuma T, Tsukada N, Kanda J, Uchida N, Ohno Y, Miyakoshi S, Kanamori H, Hidaka M, Sakura T, Onizuka M, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91(5):E284–E292. doi:10.1002/ajh.24340.
   PubMed Web of Science ®Google Scholar
• Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, Blazar BR, MacMillan ML, Weisdorf DJ. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015;125(8):1333–1338. doi:10.1182/blood-2014-10-609032.
   PubMed Web of Science ®Google Scholar
• Centuori SM, Trad M, LaCasse CJ, Alizadeh D, Larmonier CB, Hanke NT, Kartchner J, Janikashvili N, Bonnotte B, Larmonier N. Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol. 2012;92:987–997. doi:10.1189/jlb.0911465.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Stokes J, Hahn S, Hoffman E, Katsanis E. Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD. Bone Marrow Transplant. 2014;49:1076. doi:10.1038/bmt.2014.91.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Hahn S, Stokes J, Hoffman EA, Schmelz M, Proytcheva M, Chernoff J, Katsanis E. Pak2 regulates myeloid-derived suppressor cell development in mice. Blood Adv. 2017;1:1923–1933. doi:10.1182/bloodadvances.2017007435.
   PubMed Web of Science ®Google Scholar
• Kruisbeek AM, Shevach E, Thornton AM. Proliferative assays for T cell function. Curr Protoc Immunol. 2004;60(1):3. 12.11–13.12.20. doi:10.1002/0471142735.im0312s60.
   Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481. doi:10.1080/01621459.1958.10501452.
   Web of Science ®Google Scholar
• Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A (General). 1972;135:185–207. doi:10.2307/2344317.
   Google Scholar
• Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99:3493–3499. doi:10.1182/blood.V99.10.3493.
   PubMed Web of Science ®Google Scholar
• Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2−/−γc−/− Immunodeficient mice. Clin Cancer Res. 2006;12:5520. doi:10.1158/1078-0432.CCR-06-0035.
   PubMed Web of Science ®Google Scholar
• Pierini A, Colonna L, Alvarez M, Schneidawind D, Nishikii H, Baker J, Pan Y, Florek M, Kim B-S, Negrin RS, et al. Donor requirements for regulatory T cell suppression of murine graft-versus-host disease. J Immunol. 2015;195(1):347. doi:10.4049/jimmunol.1402861.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Lindberg FP, Ingulli E, Panoskaltsis-Mortari A, Oldenborg P-A, Iizuka K, Yokoyama WM, Taylor PA. CD47 (integrin-associated protein) engagement of dendritic cell and macrophage counterreceptors is required to prevent the clearance of donor lymphohematopoietic cells. J Exp Med. 2001;194(4):541–549. doi:10.1084/jem.194.4.541.
   PubMed Web of Science ®Google Scholar
• Zeiser R, Youssef S, Baker J, Kambham N, Steinman L, Negrin RS. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007;110(13):4588–4598. doi:10.1182/blood-2007-08-106005.
   PubMed Web of Science ®Google Scholar
• Malard F, Gaugler B, Lamarthee B, Mohty M. Translational opportunities for targeting the Th17 axis in acute graft-vs.-host disease. Mucosal Immunol. 2016;9:299–308. doi:10.1038/mi.2015.143.
   PubMed Web of Science ®Google Scholar
• Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, Akiba H, Yagita H, Killeen N, Taylor PA. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood. 2003;101(9):3741–3748. doi:10.1182/blood-2002-10-3048.
   PubMed Web of Science ®Google Scholar
• Cassady K, Martin PJ, Zeng D. Regulation of GVHD and GVL activity via PD-L1 interaction with PD-1 and CD80. Front Immunol. 2018;9:3061. doi:10.3389/fimmu.2018.03061.
   PubMed Web of Science ®Google Scholar
• Albring JC, Sandau MM, Rapaport AS, Edelson BT, Satpathy A, Mashayekhi M, Lathrop SK, Hsieh C-S, Stelljes M, Colonna M, et al. Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression. J Exp Med. 2010;207(12):2551–2559. doi:10.1084/jem.20102017.
   PubMed Web of Science ®Google Scholar
• Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ, Kuchroo VK, et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 2003;4(11):1102–1110. doi:10.1038/ni988.
   PubMed Web of Science ®Google Scholar
• Zhang P, Hill GR. Interleukin-10 mediated immune regulation after stem cell transplantation: mechanisms and implications for therapeutic intervention. Semin Immunol. 2019;44:101322. doi:10.1016/j.smim.2019.101322.
   PubMed Web of Science ®Google Scholar
• Henden AS, Hill GR. Cytokines in graft-versus-host disease. J Immunol. 2015;194(10):4604. doi:10.4049/jimmunol.1500117.
   PubMed Web of Science ®Google Scholar
• Wilkinson AN, Chang K, Kuns RD, Henden AS, Minnie SA, Ensbey KS, Clouston AD, Zhang P, Koyama M, Hidalgo J, et al. IL-6 dysregulation originates in dendritic cells and mediates graft-versus-host disease via classical signaling. Blood. 2019;134(23):2092–2106. doi:10.1182/blood.2019000396.
   PubMed Web of Science ®Google Scholar
• Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic Cell Regulation of Graft-Vs.-Host Disease: immunostimulation and Tolerance. Front Immunol. 2019;10:93. doi:10.3389/fimmu.2019.00093.
   PubMed Web of Science ®Google Scholar
• MacDonald KP, Shlomchik WD, Reddy P. Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Trans. 2013;19(1):S10–S14. doi:10.1016/j.bbmt.2012.11.005.
   PubMed Web of Science ®Google Scholar
• Priyadharshini B, Greiner DL, Brehm MA. T-cell activation and transplantation tolerance. Transplantation Reviews. 2012;26(3):212–222. doi:10.1016/j.trre.2011.09.002.
   Web of Science ®Google Scholar
• Thangavelu G, Blazar BR. Achievement of tolerance induction to prevent acute graft-vs.-host disease. Front Immunol. 2019;10:309. doi:10.3389/fimmu.2019.00309.
   PubMed Web of Science ®Google Scholar
• Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011;241(1):5–19. doi:10.1111/j.1600-065X.2011.01019.x.
   PubMedGoogle Scholar
• Brennan TV, Yang Y. PD-L1 serves as a double agent in separating GVL from GVHD. J Clin Invest. 2017;127(5):1627–1630. doi:10.1172/JCI94196.
   PubMed Web of Science ®Google Scholar
• Burlion A, Brunel S, Petit NY, Olive D, Marodon G. Targeting the human T-cell inducible costimulator molecule with a monoclonal antibody prevents graft-vs-host disease and preserves graft vs leukemia in a xenograft murine model. Front Immunol. 2017;8:756. doi:10.3389/fimmu.2017.00756.
   PubMed Web of Science ®Google Scholar
• Yi T, Chen Y, Wang L, Du G, Huang D, Zhao D, Johnston H, Young J, Todorov I, Umetsu DT, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101–3112. doi:10.1182/blood-2009-05-219402.
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Vallera DA, Kopf M, Young H, Longo DL, Blazar BR, et al. Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest. 1998;102(9):1742–1748. doi:10.1172/JCI3906.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, Herber DL, Schneck J, Gabrilovich DI. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828. doi:10.1038/nm1609.
   PubMed Web of Science ®Google Scholar
• Yang F, Li Y, Wu T, Na N, Zhao Y, Li W, Han C, Zhang L, Lu J, Zhao Y, et al. TNFα-induced M-MDSCs promote transplant immune tolerance via nitric oxide. J Mol Med (Berl). 2016;94(8):911–920. doi:10.1007/s00109-016-1398-z.
   PubMed Web of Science ®Google Scholar
• Veenstra RG, Flynn R, Kreymborg K, McDonald-Hyman C, Saha A, Taylor PA, Osborn MJ, Panoskaltsis-Mortari A, Schmitt-Graeff A, Lieberknecht E, et al. B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. Blood. 2015;125(21):3335–3346. doi:10.1182/blood-2014-09-603357.
   PubMed Web of Science ®Google Scholar
• Levine JE. Implications of TNF-α in the pathogenesis and management of GVHD. Int J Hematol. 2011;93:571–577. doi:10.1007/s12185-011-0803-1.
   PubMed Web of Science ®Google Scholar
• D’andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) Inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med. 1993;178:1041–1048. doi:10.1084/jem.178.3.1041.
   PubMed Web of Science ®Google Scholar
• Chaudhry A, Samstein R, Treuting P, Liang Y, Pils M, Heinrich J-M, Jack R, Wunderlich F, Brüning J, Müller W, et al. Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity. 2011;34(4):566–578. doi:10.1016/j.immuni.2011.03.018.
   PubMed Web of Science ®Google Scholar
• Park MJ, Lee SH, Lee S-H, Lee E-J, Kim E-K, Choi JY, Cho M-L. IL-1 receptor blockade alleviates graft-versus-host disease through downregulation of an interleukin-1beta-dependent glycolytic pathway in Th17 cells. Mediators Inflamm. 2015;2015:631384. doi:10.1155/2015/631384.
   PubMed Web of Science ®Google Scholar
• Lu L, Yoshimoto K, Morita A, Kameda H, Takeuchi T. Bendamustine increases interleukin-10 secretion from B cells via p38 MAP kinase activation. Int Immunopharmacol. 2016;39:273–279. doi:10.1016/j.intimp.2016.07.033.
   PubMed Web of Science ®Google Scholar
• Reshef R, Luger SM, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadtmauer EA, Smith J, Bailey S, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med. 2012;367:135–145. doi:10.1056/NEJMoa1201248.
   PubMed Web of Science ®Google Scholar
• Reshef R, Ganetsky A, Acosta EP, Blauser R, Crisalli L, McGraw J, Frey NV, Hexner EO, Hoxie JA, Loren AW, et al. Extended CCR5 blockade for graft-versus-host disease prophylaxis improves outcomes of reduced-intensity unrelated donor hematopoietic cell transplantation: a phase II clinical trial. Biol Blood Marrow Transplant. 2019;25:515–521. doi:10.1016/j.bbmt.2018.09.034.
   PubMedGoogle Scholar
• Munchel AT, Kasamon YL, Fuchs EJ. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol. 2011;24(3):359–368. doi:10.1016/j.beha.2011.05.001.
   PubMed Web of Science ®Google Scholar